Skip to main content
Uncategorized

ANGANY Now Focussing on Clinical Development

By October 21, 2024No Comments

In a context of strategic refocus but also with a heavy heart that ANGANY announces the end of activities at the R&D laboratory operated by Angany Innovation SAS in Val-de-Reuil, France. The vast potential of the eBioparticle™ had been explored for several years in this laboratory located at the heart of the Pharmaparc in this Normandy community. To these early collaborators, ANGANY extends its sincerest thanks and wishes them the best of luck in their future careers.

ANGANY needs to rebalance its resource allocation to fully support the clinical development of its 2 most advanced products: 1- ANG101, a next-generation biologic for the treatment of cat allergy in humans, and 2- ANG201, a therapeutic candidate for canine allergic dermatitis (veterinary field). More limited R&D activities will be carried out at the company’s pilot unit in Lévis, Quebec, to support: 1- a research project on a therapeutic candidate for peanut allergy, and 2- a research partnership on a novel personalized cancer therapeutic approach.